Literature DB >> 29782315

TLR4 Gene Expression and Pro-Inflammatory Cytokines in Alzheimer's Disease and in Response to Hippocampal Deafferentation in Rodents.

Justin Miron1,2,3, Cynthia Picard1,2,3, Josée Frappier1, Doris Dea1, Louise Théroux1, Judes Poirier1,2,3.   

Abstract

One important aspect in Alzheimer's disease pathology is the presence of chronic inflammation. Considering its role as a key receptor in the microglial innate immune system, TLR4 was shown to regulate the binding and phagocytosis of amyloid plaques by microglia in several mouse models of amyloidosis, as well as the production of pro-inflammatory cytokines. To our knowledge, TLR4 and its association with cytokines have not been thoroughly examined in the brains of subjects affected with Alzheimer's disease. Using quantitative reverse transcription polymerase chain reaction (qRT-PCR) in postmortem human brains, we observed increased expression for the TLR4 and TNF genes (p = 0.001 and p = 0.025, respectively), as well as a trend for higher IL6 gene expression in the frontal cortex of AD subjects when compared to age-matched controls. Similarly, using a mouse model of hippocampal deafferentation without amyloidosis, (i.e., the entorhinal cortex lesioned mouse), we observed significant increases in the expression of both the Tlr4 (p = 0.0367 and p = 0.0193 compared to sham-lesioned mice or to the contralateral side, respectively) and Il1b (p = 0.0055 and p = 0.0066 compared to sham-lesioned mice or to the contralateral side, respectively) genes in the deafferentation phase, but not during the ensuing reinnervation process. In conclusion, we suggest that the modulation of cytokines by TLR4 is differentially regulated whether by the presence of amyloid plaques or by the ongoing deafferentation process.

Entities:  

Keywords:  Alzheimer’s disease; TLR4; cytokines; inflammation

Mesh:

Substances:

Year:  2018        PMID: 29782315     DOI: 10.3233/JAD-171160

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  11 in total

Review 1.  Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.

Authors:  Meihua Luo; Leo Kit Cheung Lee; Bo Peng; Chung Hang Jonathan Choi; Wing Yin Tong; Nicolas H Voelcker
Journal:  Adv Sci (Weinh)       Date:  2022-07-18       Impact factor: 17.521

2.  Cattle Encephalon Glycoside and Ignotin Protects Neurons Against Microglia-Induced Neuroinflammation via Elevating BDNF Expression and Inhibiting TLR4/NF-κB Pathway.

Authors:  Ya Gao; Jian Zhang; Shuyue Li; Yidan Zhang; Yuan Zhao; Cui Chang; Ya Qiu; Guofeng Yang
Journal:  Neurochem Res       Date:  2020-11-13       Impact factor: 3.996

Review 3.  Microglia Polarization From M1 to M2 in Neurodegenerative Diseases.

Authors:  Shenrui Guo; Hui Wang; Yafu Yin
Journal:  Front Aging Neurosci       Date:  2022-02-16       Impact factor: 5.750

4.  Improved cognition impairment by activating cannabinoid receptor type 2: Modulating CREB/BDNF expression and impeding TLR-4/NFκBp65/M1 microglia signaling pathway in D-galactose-injected ovariectomized rats.

Authors:  Sahar S Abd El-Rahman; Hany M Fayed
Journal:  PLoS One       Date:  2022-03-29       Impact factor: 3.240

Review 5.  Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease.

Authors:  Linyu Wu; Xiaohui Xian; Guangyu Xu; Zixuan Tan; Fang Dong; Min Zhang; Feng Zhang
Journal:  Mediators Inflamm       Date:  2022-08-21       Impact factor: 4.529

6.  MicroRNAs combined with the TLR4/TDAG8 mRNAs and proinflammatory cytokines are biomarkers for the rapid diagnosis of sepsis.

Authors:  Xiyuan Xu; Baoying Bu; Hongjun Tian; Rina Wu; Jingping Yang
Journal:  Mol Med Rep       Date:  2022-09-14       Impact factor: 3.423

7.  Insights from molecular docking and molecular dynamics on the potential of vitexin as an antagonist candidate against lipopolysaccharide (LPS) for microglial activation in neuroinflammation.

Authors:  M A F Yahaya; A R Abu Bakar; J Stanslas; N Nordin; M Zainol; M Z Mehat
Journal:  BMC Biotechnol       Date:  2021-06-05       Impact factor: 2.563

8.  Neuroprotective effect of tormentic acid against memory impairment and neuro‑inflammation in an Alzheimer's disease mouse model.

Authors:  Weigang Cui; Chunli Sun; Yuqi Ma; Songtao Wang; Xianwei Wang; Yinghua Zhang
Journal:  Mol Med Rep       Date:  2020-05-18       Impact factor: 2.952

Review 9.  Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting.

Authors:  Yam Nath Paudel; Efthalia Angelopoulou; Christina Piperi; Iekhsan Othman; Khurram Aamir; Mohd Farooq Shaikh
Journal:  Cells       Date:  2020-02-07       Impact factor: 6.600

Review 10.  Role of Toll Like Receptor 4 in Alzheimer's Disease.

Authors:  Maria Calvo-Rodriguez; Carmen García-Rodríguez; Carlos Villalobos; Lucía Núñez
Journal:  Front Immunol       Date:  2020-08-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.